Bayer AG shares fell 8.34% intraday to €37.23 on 04 Mar 2026 as traders positioned ahead of the company’s earnings announcement. The move came on XETRA during active volume of 1,456,022 shares versus a three‑month average of 3,612,262. BAYN.DE stock faces focus on litigation charges, crop science trends, and drug sales for KERENDIA ahead of the results. Investors will watch guidance, cash flow, and any litigation updates that could drive a larger post‑report swing.

Earnings preview: BAYN.DE stock ahead of today’s report

Bayer (BAYN.DE) reports earnings on 04 Mar 2026 at 16:30 UTC and the market moved early. Analysts will look for segment revenue performance in Pharmaceuticals and Crop Science and litigation provisions. One metric to watch is EPS, reported at -0.20 TTM, and any management commentary on margins and buybacks.

Financial snapshot and valuation: BAYN.DE stock metrics

Bayer trades at €37.23 with market cap €37.64B and a PE of -191.55. Price to sales is 0.82 and price to book is 1.27. Free cash flow yield stands near 10.46%, while debt to equity is 1.34 and interest coverage is 2.91, highlighting leverage sensitivity.

Intraday market reaction: BAYN.DE stock technicals and flow

The intraday selloff pushed BAYN.DE below the 50‑day average of €42.21 and towards the 200‑day average of €31.73. RSI sits at 37.39 and the MACD histogram is negative, indicating short‑term momentum loss. On‑balance volume shows institutional selling pressure, with relative volume at 2.00 today.

Meyka grade and analyst consensus: BAYN.DE stock rating

Meyka AI rates BAYN.DE with a score out of 100: 68.86 (B) — HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst views. The internal company rating checklist shows mixed signals: DCF reads buy, but return metrics and leverage flag caution. These grades are not guarantees and are for informational use only.

Price targets and forecast: BAYN.DE stock outlook

Meyka AI’s forecast model projects a monthly price of €36.85, a quarterly target of €59.74, and a yearly projection of €16.08. Versus the current €37.23, the monthly forecast implies -1.01%, the quarterly implies +60.45%, and the yearly implies -56.77%. We present a practical range: conservative €32.00, base €45.00, and bullish €60.00, tied to trial outcomes and litigation clarity.

Risks and opportunities for BAYN.DE stock

Key risks include litigation rulings on weedkiller suits and crop science regulatory shifts. High net debt to EBITDA increases recession sensitivity, with net debt to EBITDA near 5.53. Opportunities include KERENDIA label expansion in CKD and pricing power in Crop Science. Upcoming data releases or trial news could swing the stock significantly.

Final Thoughts

BAYN.DE stock opened the trading day under pressure and closed the intraday move at €37.23, down €3.38 or 8.34% on higher volume. The core story for investors is clarity from tonight’s earnings on litigation provisions and near‑term guidance. Meyka AI’s forecast model projects a quarterly price of €59.74, implying +60.45% upside from today, but the yearly projection of €16.08 implies substantial downside risk. That divergence shows model sensitivity to scenario inputs. Our view remains data‑driven: if Bayer delivers clean guidance and lower litigation costs, upside toward €45.00–€60.00 is plausible. If legal charges persist and cash metrics disappoint, the stock can retest the €30.00 area. This analysis uses facts, current ratios, and Meyka AI’s model projections and is not investment advice. For context, see reporting on trading ranges at Investing.com and the latest coverage on litigation at WSJ. Meyka AI is the AI‑powered market analysis platform used for this spotlight.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.